Hone Health Secures $228 Million To Expand Physician-Led Longevity Care

Hone Health has secured $228 million in financing to expand its physician-led longevity platform, introduce new clinical programs, and develop technology that converts patient data into personalized care plans. The financing consists of $28 million in Series A equity and $200 million in growth financing from General Catalyst’s Customer Value Fund. MarcyPen Capital Partners led the equity financing, with participation from Pentland Ventures, Kinship Ventures, Hanwha, Gannet Capital, Humbition, Comma Capital, and ID Ventures.

The deal brings Hone’s total equity funding to $65 million. The company previously announced a $33 million Series A in January 2025.

David Grutman has also joined Hone as a strategic investor and adviser. Other strategic investors include Marcello Hernández, Nick Jonas, Joe Jonas, Kevin Jonas, Braxton Berrios, Kelly Rowland, Jason Strauss, Noah Tepperberg, and former NBA player Josh Childress.

Expanding Personalized Medical Programs

Hone plans to introduce and expand clinical programs covering metabolic health, inflammation, immunity, and what the company identifies as PMOS.

It will also integrate additional diagnostic services, including whole-body MRI scans, DEXA scans, coronary CT angiography, and gut microbiome analysis.

The company intends to continue developing Longevity OS, its proprietary clinical platform. The technology brings together laboratory results, health histories, symptoms, medications, and longitudinal outcomes to help physicians personalize and adjust treatment.

Hone will also expand its physician-supervised peptide program and clinical-trial infrastructure.

The company says it has treated more than 200,000 patients, administered 750,000 tests, and processed 25 million health markers.

Launching Hone Black

Hone is publicly launching Hone Black, a concierge longevity membership that has operated in stealth for approximately one year.

The program combines testing across more than 1,600 health markers with continuing care from a dedicated physician team. Potential treatments include prescription medications, supplements, peptides, lifestyle guidance, and certain exosome and stem-cell therapies.

Hone’s broader services include hormone therapy, weight management, thyroid care, cardiovascular health, and sexual health.

KEY QUOTES:

Today, consumers have almost limitless options when it comes to preventative health, but what people are looking for is the highest level of insight into their metrics, so that they can make more informed decisions about their health. Hone combines comprehensive diagnostic testing, physician-led care, and AI-powered insights to deliver that level of understanding. This funding will allow us to extend that vision across new therapeutic categories and start building toward our ultimate vision: a research platform to accelerate health outcomes.

Saad Alam, Co-Founder and CEO of Hone Health

Saad and the team at Hone are proven business builders dedicated to making it easier for people to live better, healthier lives. We believe in their vision and are proud to deepen our partnership with them.

Jay Brown, Co-Founder and Managing Partner at MarcyPen Capital Partners

When I started goop, wellness was a niche conversation. Today it’s one of the biggest categories in the world, and the next step is bringing real health and wellness to the masses, not just the few. Saad has built Hone to do exactly that, with serious science and at real scale. That’s why Kinship invested, and we could not be more excited about what’s ahead.

Gwyneth Paltrow, Founder and CEO of goop and Co-Founder of Kinship Ventures

The next great health company will be built on data. Hone has treated more than 200,000 patients and turned that into one of the largest hormone and metabolic datasets in the world, making its physicians smarter with every patient. Kinship is proud to stand alongside Saad as Hone scales.

Moj Mahdara, Co-Founder and Managing Partner of Kinship Ventures

People have never had more data about their own bodies and never less guidance on what to do with it. Hone closes that gap by pairing serious diagnostics with physicians who stay with a patient over years rather than appointments. That longitudinal relationship is the cornerstone of our Health OS thesis, and we are excited for what lies ahead for Hone.

Omar Hatteea, Investment Manager at Pentland Ventures